Sindrom pernapasan Timur Tengah: Perbedaan antara revisi
Konten dihapus Konten ditambahkan
kTidak ada ringkasan suntingan |
Ariandi Lie (bicara | kontrib) Membalikkan revisi 23482542 oleh 114.79.22.56 (bicara) spam judi Tag: Pembatalan |
||
(10 revisi perantara oleh 6 pengguna tidak ditampilkan) | |||
Baris 1:
{{Penyangkalan medis}}
{{Infobox medical condition (new)
| name = Sindrom pernapasan Timur Tengah
| image = MERS-CoV electron micrograph3.jpg
| alt =
| caption = Partikel virus MERS-CoV
| field =
| symptoms =
| complications =
| onset =
| duration = Beberapa hari hingga beberapa minggu
| types =
| causes =
| risks =
| diagnosis =
| differential =
| prevention =
| treatment =
| medication =
| prognosis =
| frequency =
| deaths =
}}
'''Sindrom pernapasan Timur Tengah''' (bahasa Inggris: ''Middle East respiratory syndrome'' atau '''MERS''') merupakan [[sindrom]] pernapasan yang sumber infeksinya adalah [[koronavirus sindrom pernapasan Timur Tengah|koronavirus - MERS]].
== Tanda dan gejala ==
Laporan awal<ref name=zaki8nov2012>{{cite journal |author=Ali Mohamed Zaki |
{{cite news
|last=Doucleef|first=Michaeleen
Baris 10 ⟶ 33:
|newspaper=Associated Press
|date=26 September 2012
}}</ref> Gejala infeksi MERS-CoV termasuk [[gagal ginjal]] dan [[pneunomia]] akut, yang
== Terapi ==
Tidak ada pengobatan yang diketahui bagi penderita MERS hingga saat ini. Beberapa terapi bisa dilakukan melalui [[inhibitor DPP4]].<ref>{{cite journal|last=Tripp|first=Ralph|title=Therapeutic Considerations for Middle East Respiratory Syndrome Coronavirus|journal=Journal of Antivirals & Antiretrovirals|date=Aug 27, 2013|volume=5|doi=10.4172/jaa.1000e109|url=http://www.omicsonline.org/therapeutic-considerations-for-middle-east-respiratory-syndrome-coronavirus-jaa.1000e109.pdf|issn=1948-5964|doi_brokendate=2014-03-22}}</ref> Perawatan terhadap penderita virus SARS bisa dijadikan dasar bagi perawatan wabah MERS-CoV;<ref>{{cite web|title=SARS Virus Treatments Could Hold the Key for Treatment of MERS-CoV Outbreak|url=http://www.sciencedaily.com/releases/2013/09/130913085711.htm|publisher=Science Daily|accessdate=19 November 2013}}</ref><ref>{{cite journal|last=Momattin|first=Hisham|coauthors=Mohammed, Khurram; Zumla, Alimuddin; Memish, Ziad A.; Al-Tawfiq, Jaffar A.|title=Therapeutic Options for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) – possible lessons from a systematic review of SARS-CoV therapy|journal=International Journal of Infectious Diseases|date=October 2013|volume=17|issue=10|pages=e792–e798|doi=10.1016/j.ijid.2013.07.002|pmid=23993766}}</ref> interferon antara α2b dan [[Ribavirin]] akan memengaruhi replikasi MERS-coV.<ref>{{cite journal|last=Coleman|first=Christopher M.|coauthors=Frieman, Matthew B.; Racaniello, Vincent|title=Emergence of the Middle East Respiratory Syndrome Coronavirus|journal=PLoS Pathogens|date=5 September 2013|volume=9|issue=9|pages=e1003595|doi=10.1371/journal.ppat.1003595|pmid=24039577|pmc=3764217}}</ref>
== Pencegahan ==
Untuk saat ini, pencegahan bisa dilakukan dengan cara memberikan [[vaksinasi influenza]] tahunan dan [[vaksinasi pneumokokus]] 5 tahunan kepada penderita untuk mengurangi atau melemahkan tingkat keparahan infeksi MERS.<ref>{{cite news|title=Novavax creates MERS-CoV vaccine candidate|author=Parrish, R.|url=http://vaccinenewsdaily.com/vaccine_development/325407-novavax-creates-mers-cov-vaccine-candidate/|newspaper=Vaccine News|date=7 June 2013|accessdate=24 June 2013}}</ref><ref>{{cite news|title=Greffex Does It Again|author=Price, J. R.|url=http://www.businesswire.com/news/home/20130626005366/en|newspaper=Business Wire|date=26 June 2013|accessdate=27 June 2013}}</ref>
== Referensi ==
{{reflist}}
{{Penyakit-stub}}
{{Authority control}}
[[Kategori:Penyakit]]
[[
[[Kategori:Penyakit viral]]
[[Kategori:Penyakit menular]]
|